Radiation Therapy for Non-Small Cell Lung Cancer (NSCLC)

  • Hak Choy
  • Anuradha Chakravarthy
  • Jae-Sung Kim
Part of the Cancer Treatment and Research book series (CTAR, volume 105)


The year 1995 marked the centennial of Roentgen’s landmark discovery of x-rays in 1895 (1). “A new kind of ray”, which was emitted by a gas discharge tube, could blacken photographic film. Almost immediately, its applications to medicine were recognized. It was used to locate a piece of knife in the backbone of a sailor who had been paralyzed until the fragment could be located and removed. X-rays were first used therapeutically in 1897 when Leopold Freund, a German surgeon, successfully irradicated a hairy mole using the new technique (2). By 1934 Coutard developed a protracted, fractionated scheme for the successful treatment of laryngeal cancer (3).


Lung Cancer Intensity Modulate Radiation Therapy Radiation Therapy Oncology Group Combine Modality Therapy Superior Vena CAVA Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. C. Roentzen. “On a New Kind of Rays (Preliminary Communication)”-Translation of a paper read before the Physikalische-Medicinischen Gesellschaft of Wurzburg on December 28, 1895.British Journal of Radiology4 (32), 1931.CrossRefGoogle Scholar
  2. 2.
    H.D. Kogelnik. Inauguration of radiotherapy as a new scientific speciality by Leopold Freund 100 years ago [see comments].Radiother.Oncol.42 (3):203–211, 1997.PubMedCrossRefGoogle Scholar
  3. 3.
    H. Coutard. Pinciples of x-ray therapy of malignant diseases.Lancet2:1–8, 1934.CrossRefGoogle Scholar
  4. 4.
    P Curie, M. P. Curie, and G. Bemont. Sur Une Nouvell Substance Fortement Radioactive Contenue dans la Peckblende (Note presented by M. Becquerel).Complete Rendition of Academy of Sciences (Paris)127:1215–1217, 1898.Google Scholar
  5. 5.
    C. F. Mountain. Revisions in the International System for Staging Lung Cancer [see comments].Chest111 (6):1710–1717, 1997.PubMedCrossRefGoogle Scholar
  6. 6.
    H. M. Sandler, W. J. Curran, Jr., and A. T. Turrisi, III. The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer.Int.J.Radiat.Oncol.Biol.Phys.19 (1):9–13, 1990.PubMedCrossRefGoogle Scholar
  7. 7.
    E. M. Noordijk, Clement E. Poest, J. Hermans, A. M. Weyer, and J. W. Leer. Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer.Radiother.Oncol.13 (2):83–89, 1988.PubMedCrossRefGoogle Scholar
  8. 8.
    H. X. Zhang, W. B. Yin, L. J. Zhang, Z. Y. Yang, Z. X. Zhang, M. Wang, D. F. Chen, and X. Z. Gu. Curative radiotherapy of early operable non-small cell lung cancer.Radiother.Oncol.14 (2):89–94, 1989.PubMedCrossRefGoogle Scholar
  9. 9.
    D. E. Dosoretz, M. J. Katin, P. H. Blitzer, J. H. Rubenstein, S. Salenius, M. Rashid, R. A. Dosani, G. Mestas, A. D. Siegel, and T. T. Chadha. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies [see comments].Int.J.Radiat.Oncol.Biol.Phys.24 (1):3–9, 1992.PubMedCrossRefGoogle Scholar
  10. 10.
    R. Gelman, R. Gelber, I. C. Henderson, C. N. Coleman, and J. R. Harris. Improved methodology for analyzing local and distant recurrence [see comments].J. Clin.Oncol.8 (3):548–555, 1990.PubMedGoogle Scholar
  11. 11.
    G. S. Sibley, T. A. Jamieson, L. B. Marks, M. S. Anscher, and L. R. Prosnitz. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.Int.J.Radiat.Oncol.Biol.Phys.40 (1):149–154, 1998.PubMedCrossRefGoogle Scholar
  12. 12.
    A. D. Krol, P. Aussems, E. M. Noordijk, J. Hermans, and J. W. Leer. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?Int.JRadiat.Oncol.Biol.Phys.34 (2):297–302, 1996.CrossRefGoogle Scholar
  13. 13.
    T. Naruke, T. Goya, R. Tsuchiya, and K. Suemasu. Prognosis and survival in resected lung carcinoma based on the new international staging system [published erratum appears in J Thorac Cardiovasc Surg 1989 Mar;97(3):350].J.Thorac.Cardiovasc.Surg.96 (3):440–447, 1988.PubMedGoogle Scholar
  14. 14.
    D. E. Dosoretz, D. Galmarini, J. H. Rubenstein, M. J. Katin, P. H. Blitzer, S. A. Salenius, R. A. Dosani, M. Rashid, G. Mestas, and S. E. Hannan. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication.Int.J.Radiat.Oncol.Biol.Phys.27 (3):507–516, 1993.PubMedCrossRefGoogle Scholar
  15. 15.
    Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group.N.Eng1.J.Med.315 (22):1377–1381, 1986.CrossRefGoogle Scholar
  16. 16.
    Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group [see comments].Lancet352 (9124):257–263, 1998.Google Scholar
  17. 17.
    S. M. Keller. ECOG: Phase III comparison of thoracic radiotherapy alone Vs combined with CDDPNP-16 chemotherapy as postoperative adjuvant therapy for Stage II/IIIA non-scall cell lung cancer, Closed 02/04/97. PASCO, 1999.Google Scholar
  18. 18.
    N. Martini, M. G. Kris, R. J. Gralla, M. S. Bains, P. M. McCormack, L. R. Kaiser, M. E. Burt, and M. B. Zaman. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 MO).Ann.Thorac.Surg.45 (4):370–379, 1988.PubMedCrossRefGoogle Scholar
  19. 19.
    V. W. Rusch, K. S. Albain, J. J. Crowley, T. W. Rice, V. Lonchyna, R. McKenna, Jr. R. B. Livingston, B. R. Griffin, and J. R. Benfield. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J. Thorac. Cardiovasc. Surg.105 (1):97–104, 1993.PubMedGoogle Scholar
  20. 20.
    J. A. Roth, F. Fossella, R. Komaki, M. B. Ryan, J. B. Putnam, Jr. J. S. Lee, H. Dhingra, L. De Caro, M. Chasen, and M. McGavran. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer [see comments].J.Natl.Cancer Inst.86 (9):673–680, 1994.PubMedCrossRefGoogle Scholar
  21. 21.
    Rosell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153–158, 1994.PubMedCrossRefGoogle Scholar
  22. 22.
    T. Sause, P. Koselar, S. Taylor, D. Johnson, R. Livingston, R. Komaki, B. Emami, W. Curran, R. Byhardt, B. Fisher, and A. T. Turrisi. Five-year Results; Phase III trial of regionally advanced unresectable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992.Proceeding of the American Society of Clinical Oncology1998:1743, 1998. (Abstract)Google Scholar
  23. 23.
    K. Kubota, K. Furuse, M. Kawahara, N. Kodama, M. Yamamoto, M. Ogawara, S. Negoro, N. Masuda, M. Takada, and K. Matsui. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer.J. Clin.Oncol.12 (8):1547–1552, 1994.PubMedGoogle Scholar
  24. 24.
    R. O. Dillman, S. L. Seagren, K. J. Propert, J. Guerra, W. L. Eaton, M. C. Perry, R. W. Carey, E. F. Frei ,III, and M. R. Green.A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III nonsmall-cell lung cancer [see comments].N.Engl.J.Med.323 (14):940–945, 1990.PubMedCrossRefGoogle Scholar
  25. 25.
    W. T. Sause, C. Scott, S. Taylor, D. Johnson, R. Livingston, R. Komaki, B. Emami, W. J. Curran, R. W. Byhardt, and A. T. Turrisi. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall-cell lung cancer.J.Natl.Cancer Inst.87 (3):198–205, 1995.PubMedCrossRefGoogle Scholar
  26. 26.
    T. Le Chevalier, R. Arriagada, E. Quoix, P. Ruffle, M. Martin, M. Tarayre, M. J. Lacombe-Terrier, J. Y. Douillard, and A. Laplanche. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients [see comments].J.Natl.Cancer Inst.83 (6):417–423, 1991.PubMedCrossRefGoogle Scholar
  27. 27.
    R. Arriagada, T. Le Chevalier, and E Rekacewicz. Cisplatin-Based Chemoradiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer(NSCLC: Late Analysis of a French Randomized Trial (abstract).Proceeding of the American Society of Clinical Oncology16:446a,1997. (Abstract)Google Scholar
  28. 28.
    C. Schaake-Koning, Bogaert W. van den, O. Dalesio, J. Festen, J. Hoogenhout, P. van Houtte, A. Kirkpatrick, M. Koolen, B. Maat, and A. Nijs. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer [seecomments]. N.Eng1.J.Med.326 (8):524–530, 1992.CrossRefGoogle Scholar
  29. 29.
    K. S. Albain, V. W. Rusch, J. J. Crowley, T. W. Rice, A. T. Turrisi, III, J. K. Weick, V. A. Lonchyna, C. A. Presant, R. J. McKenna, and D. R. Gandara. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.J.Clin.Oncol.13 (8):1880–1892, 1995.PubMedGoogle Scholar
  30. 30.
    K. Mattson, L. R. Holsti, P. Holsti, M. Jakobsson, M. Kajanti, K. Liippo, M. Mantyla, S. Niitamo-Korhonen, V. Nikkanen, and E. Nordman. Inoperable non-small cell lung cancer: radiation with or without chemotherapy.Eur.J. Cancer Clin.Oncol.24 (3):477–482, 1988.PubMedCrossRefGoogle Scholar
  31. 31.
    P. van Houtte, J. Klastersky, A. Renaud, J. Michel, G. Vandermoten, H. Nguyen, J. P. Sculier, J. Devriendt, and P. Mommen. Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for nonsmall-cell lung cancer. A randomized study.Antibiot.Chemother.41:131–137, 1988.PubMedGoogle Scholar
  32. 32.
    L. Critic), P. Latini, M. Meacci, E. Corgna, E. Maranzano, S. Darwish, V. Minotti, A. Santucci, and M. Tonato. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer.Ann.Oncol.4 (10):847–851, 1993.Google Scholar
  33. 33.
    A. Planting, P. Helle, P. Drings, O. Dalesio, A. Kirkpatrick, G. McVie, and G. Giaccone. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial [see comments].Ann.Oncol.7 (2):139–144, 1996.Google Scholar
  34. 34.
    R. F. Morton, J. R. Jett, W. L. McGinnis, J. D. Earle, T. M. Therneau, J. E. Krook, T. E. Elliott, J. A. Mailliard, R. A. Nelimark, and A. W. Maksymiuk. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial [see comments]. Ann.Intern.Med.115 (9):681–686, 1991.PubMedGoogle Scholar
  35. 35.
    Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group [see comments].BMJ311 (7010):899–909, 1995.Google Scholar
  36. 36.
    P. Marino, A. Preatoni, and A. Cantoni. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis [see comments].Cancer76 (4):593–601, 1995.PubMedCrossRefGoogle Scholar
  37. 37.
    R. S. Pritchard and S. P. Anthony. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-smallcell lung cancer. A meta-analysis [published erratum appears in Ann Intern Med 1997 Apr 15;126(8):670]. Ann.Intern.Med.125(9):723–729, 1996.PubMedGoogle Scholar
  38. 38.
    R. W. Byhardt, C. Scott, W. T. Sause, B. Emami, R. Komaki, B. Fisher, J. S. Lee, and C. Lawton. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.Int.J.Radiat.Oncol.Biol.Phys.42 (3):469–478, 1998.PubMedCrossRefGoogle Scholar
  39. 39.
    K. Furose, M. Fukuoka, and M. Takada. A Randomized Phase II Study of Concurrent vs. Sequential Thoracic Radiotherapy in Combination with Mitomycin, Vindesine adn Cisplatin in Unresectable Stage III NSCLC: Preliminary Analysis.Proceeding of the American Society of Clinical Oncology16: 1999. (Abstract)Google Scholar
  40. 40.
    G. Clamon, J. Herndon, R. Cooper, A. Y. Chang, J. Rosenman, and M. R. Green. Radiosensitization with carboplatin for patients with unresectable stage III nonsmall-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group [see comments].1Clin.Oncol.17 (1):411, 1999.Google Scholar
  41. 41.
    Curran WJ, Scott C, Langer C, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal S, Byhardt R, Sause W, Cox J. Phase III comparison of sequential vs. concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. PASCO 2000 Abstract No. 1891.Google Scholar
  42. 42.
    W. T. Sause, C. Scott, S. Taylor, D. Johnson, R. Livingston, R. Komaki, B. Emami, W. J. Curran, R. W. Byhardt, and A. T. Turrisi. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall-cell lung cancer.J.Natl.CancerInst.87 (3):198–205, 1995.CrossRefGoogle Scholar
  43. 43.
    Byhardt, C. B. Scott, D. S. Ettinger, W. J. Curran, R. L. Doggett, C. Coughlin, C. Scarantino, M. Rotman, and B. Emami. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90–15.Cancer75 (9):2337–2344, 1995.PubMedCrossRefGoogle Scholar
  44. 44.
    R. Komaki, C. Scott, D. Ettinger, J. S. Lee, F. V. Fossella, W. Curran, R. F. Evans, P. Rubin, and R. W. Byhardt. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92–04.Int.J.Radiat.Oncol.Biol.Phys.38 (1):149–155, 1997.PubMedCrossRefGoogle Scholar
  45. 45.
    T. A. Salerno, D. D. Munro, P. E. Blundell, and R. C. Chiu. Second primary bronchogenic carcinoma: life-table analysis of surgical treatment.Ann. Thorac. Surg.27 (1):3–6, 1979.PubMedCrossRefGoogle Scholar
  46. 46.
    A. Yellin, L. R. Hill, and J. R. Benfield. Bronchogenic carcinoma associated with upper aerodigestive cancers.J.Thorac.Cardiovasc.Surg.91 (5):674–683, 1986.PubMedGoogle Scholar
  47. 47.
    B. A. Armstrong, C. A. Perez, J. R. Simpson, and M. A. Hederman. Role of irradiation in the management of superior vena cava syndrome.Int.JRadiat.Oncol.Biol.Phys.13 (4):531–539, 1987.CrossRefGoogle Scholar
  48. 48.
    C. P. Escalante. Causes and management of superior vena cava syndrome.Oncology (Huntingt)7 (6):61–68, 1993.Google Scholar
  49. 49.
    D. E. Schraufnagel, R. Hill, J. A. Leech, and J. A. Pare. Superior vena caval obstruction. Is it a medical emergency?Am.J.Med.70 (6):1169–1174, 1981.PubMedCrossRefGoogle Scholar
  50. 50.
    A. M. Maddox, M. Valdivieso, J. Lukeman, T. L. Smith, H. E. Barkley, M. L. Samuels, and G. P. Bodey. Superior vena cava obstruction in small cell bronchogenic carcinoma. Clinical parameters and survival.Cancer52 (11):2165–2172, 1983.PubMedCrossRefGoogle Scholar
  51. 51.
    Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.J. Clin.Oncol.15 (8):2996–3018, 1997.Google Scholar
  52. 52.
    Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party.Br.J.Cancer63 (2):265–270, 1991.Google Scholar
  53. 53.
    P. Teo, T. H. Tai, D. Choy, and K. H. Tsui. A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung.Int.J.Radiat.Oncol.Biol.Phys.14 (5):867–871, 1988.PubMedCrossRefGoogle Scholar
  54. 54.
    L. Mandell, B. Hilaris, M. Sullivan, N. Sundaresan, D. Nori, J. H. Kim, N. Martini, and Z. Fuks. The treatment of single brain metastasis from non-oat cell lung carcinoma. Surgery and radiation versus radiation therapy alone.Cancer58 (3):641–649, 1986.PubMedGoogle Scholar
  55. 55.
    L. M. DeAngelis, L. R. Mandell, H. T. Thaler, D. W. Kimmel, J. H. Galicich, Z. Fuks, and J. B. Posner. The role of postoperative radiotherapy after resection of single brain metastases.Neurosurgery24 (6):798–805, 1989.PubMedCrossRefGoogle Scholar
  56. 56.
    Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 22:322:494–500, 1990.Google Scholar
  57. 57.
    Alexander E 3rdMoriarty TM, Davis RB, Wen PY, Fine HA, Black PM, Kooy HM, Loeffler JS. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst 87:34–40, 1995.PubMedCrossRefGoogle Scholar
  58. 58.
    C. A. Perez, M. Bauer, S. Edelstein, B. W. Gillespie, and R. Birch. Impact of tumor control on survival in carcinoma of the lung treated with irradiation [published erratum appears in Int J Radiat Oncol Biol Phys 1986 Nov;12(1l):2057].Int.J.Radiat.Oncol.Biol.Phys.12 (4):539–547, 1986.PubMedCrossRefGoogle Scholar
  59. 59.
    J. D. Cox, N. Azarnia, R. W. Byhardt, K. H. Shin, B. Emami, and T. F. Pajak. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III nonsmall-cell lung carcinoma: report of Radiation Therapy Oncology Group 83–11.J.Clin.Oncol.8 (9):1543–1555, 1990.PubMedGoogle Scholar
  60. 60.
    M. Saunders, S. Dische, A. Barrett, A. Harvey, D. Gibson, and M. Parmar. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee [see comments].Lancet350 (9072):161–165, 1997.PubMedCrossRefGoogle Scholar
  61. 61.
    A. J. Bailey, M. K. Parmar, and R. J. Stephens. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee.J. Clin. Oncol.16 (9):3082–3093, 1998.PubMedGoogle Scholar
  62. 62.
    M. P. Mehta, S. P. Tannehill, S. Adak, L. Martin, D. G. Petereit, H. Wagner, J. F. Fowler, and D. Johnson. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593.J.Clin.Oncol.16 (11):3518–3523, 1998.PubMedGoogle Scholar
  63. 63.
    Choy H, Devore RF 3`dHande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47:931–937, 2000.PubMedCrossRefGoogle Scholar
  64. 64.
    J. S. Lee, C. Scott, R. Komaki, F. V. Fossella, G. S. Dundas, S. McDonald, R. W. Byhardt, and W. J. Curran, Jr. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91–06.J.Clin.Oncol.14 (4):1055–1064, 1996.Google Scholar
  65. 65.
    M. V. Graham, M. Jahanzeb, C. M. Dresler, J. D. Cooper, B. Emami, and J. E. Mortimer. Results of a trial with topotecan dose escalation and concurrent thoracic radiation therapy for locally advanced, inoperable nonsmall cell lung cancer.Int.J.Radiat.Oncol.Biol.Phys.36 (5):1215–1220, 1996.PubMedCrossRefGoogle Scholar
  66. 66.
    A. Vanagunas, P. Jacob, and E. Olinger. Radiation-induced esophageal injury: a spectrum from esophagitis to cancer.Am.J.Gastroenterol.85 (7):808–812, 1990.PubMedGoogle Scholar
  67. 67.
    T. R. Mackie, T. Holmes, S. Swerdloff, P. Reckwerdt, J. O. Deasy, J. Yang, B. Paliwal, and T. Kinsella. Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy.Med.Phys.20 (6):1709–1719, 1993.PubMedCrossRefGoogle Scholar
  68. 68.
    M. P. Carol. Integrated 3D conformal plannin/multivane intesity modulatin delivery system for radiotherapy. In:3D Radiaiton Treatemtn Planning and Conformal Therapyedited by J. A. Purdy and B. Emami, Madison, WI:Medical Physics Publishing, 1995, p. 435–445.Google Scholar
  69. 69.
    D. J. Convery and M. E. Rosenbloom. The generation of intesity-modulated fields for the conformal radiotherapy by dynamic collimationPhysics in medicine & biology37:1359, 1992.CrossRefGoogle Scholar
  70. 70.
    T. Bortfeld, A. L. Boyer, W. Schlegel, D. L. Kahler, and T. J. Waldron. Realization and verification of three-dimensional conformal radiotherapy with modulated fields [see comments].Int.J.Radiat.Oncol.Biol.Phys.30 (4):899–908, 1994.PubMedCrossRefGoogle Scholar
  71. 71.
    S. V. Spirou and C. S. Chui. Generation of arbitrary intensity profiles by dynamic jaws or multileaf collimators.Med.Phys.21 (7):1031–1041, 1994.PubMedCrossRefGoogle Scholar
  72. 72.
    T. Bortfeld, D. L. Kahler, and T. J. Waldron. X-ray field compensation with multi-leaf collimatersInt.J.Radiat.Oncol.Biol.Phys.28:723, 1994.PubMedCrossRefGoogle Scholar
  73. 73.
    C. X. Yu, M. J. Symons, M. N. Du, A. A. Martinez, and J. W. Wong. A method for implementing dynamic photon beam intensity modulation using independent jaws and a multileaf collimator.Phys.Med.Biol.40 (5):769–787, 1995.PubMedCrossRefGoogle Scholar
  74. 74.
    C. X. Yu. Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy.Phys.Med.Biol.40 (9):1435–1449, 1995.PubMedCrossRefGoogle Scholar
  75. 75.
    J. Stein, K Hartwig, S Levegrun, and et al. Intesity-modulated treatments: Compensators vs. multi-leaf modulation. In:XII International conference on theedited by D. D. Leavitt and G. Starkschall, 1999.Google Scholar
  76. 76.
    Dubal N, Chans, Cullip T, et al. Intensity modulation for tangential breast treatment. Int J Radiat Oncol Biol Phys 42:127, 1998.Google Scholar
  77. 77.
    Mehta M, Petereit D, Chosey L, et al. Sequential comparison of low dose rate and hyperfractionated high dose rate endobronchial radiation for malignant airway occlusion. Int J Radiat Oncol Biol Phys 23:133, 1992.Google Scholar
  78. 78.
    Speiser B. Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 25:579, 1993.PubMedCrossRefGoogle Scholar
  79. 79.
    Taulelle M, Chauvet B, Vincent P, et al. High dose rate endobronchial brachytherapy; results and complications in 189 patients. 11:162, 1998.Google Scholar
  80. 80.
    Hennequin C, Tredanial J, Durdux C, et al. Endobronchial brachytherapy: the Saint Louis Hospital experience. Cancer Radiother 1:159, 1997.PubMedCrossRefGoogle Scholar
  81. 81.
    Gollins SW, Ryder WDJ, Burt PV, et al. Massive haemoptysis death and other morbidity associated with high dose rate inraluiminal radiotherapy for carcinoma of the bronchus. Radiother Oncol 39:105, 1996.PubMedCrossRefGoogle Scholar
  82. 82.
    Huber RM, Fischer R, Hautmann H, et al. Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 43:533, 1997.CrossRefGoogle Scholar
  83. 83.
    Ornadel D, Duchesene G, Wall P, et al. Defining the roles of high dose rate endobronchial brachytherapy and laser resection for recurrent bronchial malignancy. In Hansen HH (ed): Lung Cancer 16, pp 203–213, New York, NY, Elsevier, 1997.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Hak Choy
    • 1
  • Anuradha Chakravarthy
    • 2
  • Jae-Sung Kim
    • 3
  1. 1.Vanderbilt University Medical CenterNashvilleUSA
  2. 2.Vanderbilt University Medical CenterNashvilleUSA
  3. 3.Vanderbilt University Medical CenterNashvilleUSA

Personalised recommendations